Global Personalized Cell Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Personalized Cell Therapy Market Research Report 2024
The patient-tailored therapies for the treatment of variety of disease are known as personalized cell therapy. The personalized cell therapy is based on genomic profile, and disease prevalence/severity and the drug developed by this therapy target the patients who matches the specific disease physiopathology and/or patient characteristics.The personalized cell therapy is mainly developed for the treatment of high unmet need disease
According to MRAResearch’s new survey, global Personalized Cell Therapy market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Personalized Cell Therapy market research.
Key companies engaged in the Personalized Cell Therapy industry include Novartis AG, Vericel Corporation, Bellicum Pharmaceuticals, MolMed SpA, Cytori Therapeutics Inc, Gilead Sciences, Inc, Celgene Corporation, Bluebird Bio and Aurora Biopharma Inc, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Personalized Cell Therapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Personalized Cell Therapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Personalized Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis AG
Vericel Corporation
Bellicum Pharmaceuticals
MolMed SpA
Cytori Therapeutics Inc
Gilead Sciences, Inc
Celgene Corporation
Bluebird Bio
Aurora Biopharma Inc
Saneron CCEL Therapeutics,Inc
Kuur Therapeutics
MediGene AG
Sangamo Therapeutics
Segment by Type
By Cell Type
Hematopoietic Stem Cell
Skeletal Muscle Stem Cell
Mesenchymal Stem Cells
Lymphocytes
Others
By Technique
Platelet Transfusions
Bone Marrow Transplantation
Packed Red Cell Transfusions
Organ Transplantation
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Personalized Cell Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Personalized Cell Therapy market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Personalized Cell Therapy market research.
Key companies engaged in the Personalized Cell Therapy industry include Novartis AG, Vericel Corporation, Bellicum Pharmaceuticals, MolMed SpA, Cytori Therapeutics Inc, Gilead Sciences, Inc, Celgene Corporation, Bluebird Bio and Aurora Biopharma Inc, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Personalized Cell Therapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Personalized Cell Therapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Personalized Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Vericel Corporation
Bellicum Pharmaceuticals
MolMed SpA
Cytori Therapeutics Inc
Gilead Sciences, Inc
Celgene Corporation
Bluebird Bio
Aurora Biopharma Inc
Saneron CCEL Therapeutics,Inc
Kuur Therapeutics
MediGene AG
Sangamo Therapeutics
Segment by Type
By Cell Type
Hematopoietic Stem Cell
Skeletal Muscle Stem Cell
Mesenchymal Stem Cells
Lymphocytes
Others
By Technique
Platelet Transfusions
Bone Marrow Transplantation
Packed Red Cell Transfusions
Organ Transplantation
Segment by Application
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Personalized Cell Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source